Literature DB >> 6733701

Venous thrombosis as a side effect of tamoxifen treatment.

A Lipton, H A Harvey, R W Hamilton.   

Abstract

We report what we believe to be an infrequent but noteworthy complication of antiestrogen therapy with tamoxifen. Seven patients developed venous thrombosis or pulmonary embolism within 6 months of starting treatment. Guidelines similar to those employed in younger women treated with anovulatory drugs would appear indicated.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6733701

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  18 in total

1.  A lipid-modified estrogen derivative that treats breast cancer independent of estrogen receptor expression through simultaneous induction of autophagy and apoptosis.

Authors:  Sutapa Sinha; Sayantani Roy; Bathula Surendar Reddy; Krishnendu Pal; Godeshala Sudhakar; Seethalakshmi Iyer; Shamit Dutta; Enfeng Wang; Pawan Kumar Vohra; Karnati Rammohan Roy; Pallu Reddanna; Debabrata Mukhopadhyay; Rajkumar Banerjee
Journal:  Mol Cancer Res       Date:  2011-02-02       Impact factor: 5.852

Review 2.  Endocrine therapy of metastatic breast cancer.

Authors:  A Manni
Journal:  J Endocrinol Invest       Date:  1989-05       Impact factor: 4.256

3.  Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms.

Authors:  Nicole C Kleinstreuer; Jian Yang; Ellen L Berg; Thomas B Knudsen; Ann M Richard; Matthew T Martin; David M Reif; Richard S Judson; Mark Polokoff; David J Dix; Robert J Kavlock; Keith A Houck
Journal:  Nat Biotechnol       Date:  2014-05-18       Impact factor: 54.908

Review 4.  Tamoxifen and mastalgia. An emerging indication.

Authors:  I S Fentiman
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

5.  Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels.

Authors:  G Bertelli; P Pronzato; D Amoroso; M P Cusimano; P F Conte; G Montagna; S Bertolini; R Rosso
Journal:  Breast Cancer Res Treat       Date:  1988-12       Impact factor: 4.872

Review 6.  Tamoxifen in the prevention of breast cancer. Are the risks likely to outweigh the benefits?

Authors:  M O'Brien; T J Powles
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

Review 7.  Clinical pharmacology of selective estrogen receptor modulators.

Authors:  B Haynes; M Dowsett
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

8.  Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.

Authors:  Judy E Garber; Susan Halabi; Sara M Tolaney; Ellen Kaplan; Laura Archer; James N Atkins; Stephen Edge; Charles L Shapiro; Lynn Dressler; Electra D Paskett; Electra M Paskett; Gretchen Kimmick; James Orcutt; Anthony Scalzo; Eric Winer; Ellis Levine; Nasir Shahab; Nancy Berliner
Journal:  J Natl Cancer Inst       Date:  2010-06-16       Impact factor: 13.506

Review 9.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

10.  Chemoprevention of breast cancer.

Authors:  T J Powles; J R Hardy; S E Ashley; D Cosgrove; J B Davey; M Dowsett; A McKinna; A G Nash; S K Rundle; H D Sinnett
Journal:  Breast Cancer Res Treat       Date:  1989-10       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.